河北医科大学学报

• 论著 • 上一篇    下一篇

阿托伐他汀和瑞舒伐他汀对非糖尿病脑梗死二级预防患者血糖的影响

  

  1. 1.冀中能源峰峰集团有限公司九龙服务分公司医院内科,河北 邯郸 056500;2.冀中能源峰峰集团有限公司总医院
    神经内科,河北 邯郸 056200;3.冀中能源峰峰集团有限公司总医院药学部,河北 邯郸 056200
  • 出版日期:2019-12-25 发布日期:2018-12-29
  • 作者简介:陈梅(1972-),女,四川荣县人,冀中能源峰峰集团有限公司九龙服务分公司医院副主任护师,从事临床护理学研究。
  • 基金资助:
    河北省医学科学研究重点课题(20181744)

Effects of atorvastatin and rosuvastatin on blood glucose in patients with nondiabetes but with cerebral infarction secondary prevention#br#

  1. 1.Department of Internal Medicine, Jiulong Service Branch Hospital of Jizhong Energy Fengfeng
    Group Co., LTD., Hebei Province,Handan 056500, China; 2.Department of Neurology, General
    Hospital of Jizhong Energy Fengfeng Group Co., LTD., Hebei Province, Handan 056200,
    China; 3.Department of Pharmacy, General Hospital of Jizhong Energy Fengfeng Group Co., LTD., Hebei Province, Handan 056200, China
  • Online:2019-12-25 Published:2018-12-29

摘要: [摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察非糖尿病脑梗死二级预防患者服用不同剂量阿托伐他汀和瑞舒伐他汀调控血脂时血糖相关指标的变化。
〖HTH〗方法〖HTSS〗〖KG*2〗将150例患者随机分为5组各30例,分别给予阿托伐他汀钙片10 mg、20 mg、40 mg和瑞舒伐他汀钙片10 mg、20 mg,口服,每晚1次。疗程均为24周。观察治疗前后空腹三酰甘油(triglyceride,TG)、总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDLC)、空腹血糖(fasting blood glucose,FBG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)的变化。
〖HTH〗结果〖HTSS〗〖KG*2〗治疗后,阿托伐他汀10 mg组、20 mg组、40 mg组和瑞舒伐他汀10 mg组、20 mg组TG、TC、 LDLC较治疗前明显下降,阿托伐他汀20 mg组HbA1c较治疗前升高,阿托伐他汀40 mg组FBG和HbA1c较治疗前升高(P<005);治疗后,阿托伐他汀20 mg组、40 mg组和瑞舒伐他汀10 mg组、20 mg组TG、TC、 LDLC低于阿托伐他汀10 mg组,阿托伐他汀40 mg组TG、TC、 LDLC又低于20 mg组和瑞舒伐他汀10 mg组,瑞舒伐他汀20 mg组低于10 mg组(P<005),阿托伐他汀40 mg组HbA1c高于阿托伐他汀10 mg组、20 mg组和瑞舒伐他汀10 mg组、20 mg组(P<005)。
〖HTH〗结论〖HTSS〗〖KG*2〗瑞舒伐他汀降脂效果与阿托伐他汀相同时对FBG和HbA1c影响较小。

关键词: 脑梗死, 阿托伐他汀, 瑞舒伐他汀

Abstract: [Abstract] Objective〖HTSS〗〓To observe the level changes of blood glucose related indexes in patients with nondiabetes but with cerebral infarction secondary prevention, when they took different doses of atorvastatin or rosuvastatin to regulate blood lipids.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓One  hundred and fifty patients were randomly divided into 5 groups, 30 patients in each group. They were respectively treated with 10 mg atorvastatin, 20 mg atorvastatin, 40 mg atorvastatin, 10 mg rosuvastatin or 20 mg rosuvastatin by oral  administration once a night. The course of treatment was 24 weeks. The level changes of fasting triglyceride(TG), total cholesterol(TC), low density lipoprotein cholesterol(LDLC), fasting blood glucose(FBG) and glycosylated hemoglobin(HbA1c) in those patients were observed before and after treatment.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After treatment, the level of TG, TC and LDLC of each group were significantly decreased, HbA1c level of 20 mg atorvastatin group was significantly increased and the level of FBG and HbA1c of 40 mg atorvastatin group were significantly increased(P<005). Pairwise comparison among groups after treatment: the level of TG, TC and LDLC of 10 mg atorvastatin group were significantly higher than those of other four groups, those of 40 mg atorvastatin group were significantly lower than those of 20 mg atorvastatin group and two rosuvastatin groups. Those of 20 mg rosuvastatin group were significantly lower than those of 10 mg rosuvastatin group(P<005). HbA1c level of 40 mg atorvastatin group were significantly higher than that of other four groups(P<005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The effect of rosuvastatin on FBG and HbA1c is less than that of atorvastatin when the lipidlowering effect of rosuvastatin is the same as that of atorvastatin.

Key words: brain infarction; atorvastatin, rosuvastatin